P228 Comparing cardiometabolic risk indicators between adults post-hospitalisation with COVID-19 and healthy controls

P228 Table 1Comparing cardiometabolic measures between adults post-hospitalisation with COVID-19 and healthy controlsMeasure N= Adults post-hospitalisation with COVID-19 N= Adult Healthy controls Mean between group difference [SD] Age, years 38 62 [9] 17 62 [9] Comorbidities01More than 2 38 12 (31.6%)13 (34.2%)13 (34.2%) 17 15 (88.2%)1 (5.9%)1 (5.9%) Body mass index, kg/m2 38 30.1 [26.7–33.6] 17 24.9 [22.4–26.4] 5.86 [4.15] Resting systolic blood pressure, mmHg 38 142 [133–151] 16 114 [104–132] 25 [18] Resting diastolic blood pressure, mmHg 38 74 [68–80] 16 84 [77–87] -7 [5] Resting heart rate, beats/min 38 63 [59–73] 16 71 [61–77] -4 [3] Glucose, mmol/L 34 5.3 [4.9–5.7] 12 4.8 [4.5–5.1] 1.2 [0.9] Haemoglobin A1c, mmol/L 36 5.8 [5.3–6.2] 11 5.4 [5.3–5.6] 0.5 [0.4] HOMA-IR 23 2.8 [1.8–5.6] 11 1.1 [0.5–2.1] 4.8 [3.4] VO2 peak (ml/min/kg) 24 13.9 [11.6–19.7] 13 33.7 [24.8–36.4] -16.5 [11.7] Carotid-femoral pulse wave velocity, m/s 37 9.50 [8.15–11.50] 9 7.30 [6.75–10.45] 1.44 [1.02] Brachial-ankle pulse wave velocity, m/s 35 15.80 [13.60–17.50] 9 11.80 [11.0–14.90] 2.62 [1.85] Data presented as mean [SD] or median [IQR] depending on distributionOne participant in the post-COVID-19 group was taking beta-blockersConclusionsThis exploratory cross-sectional study shows that routinely used clinical tests of cardiometabolic risk indicate higher future risk for adults post-COVID compared to healthy controls. More detailed measures of cardiometabolic risk support this finding. It is unclear whether acute COVID-19 further contributes to pre-existing cardiometabolic risk. However, our small exploratory study supports the need for interventions such as aerobic exercise training which are proven to reduce aortic stiffness in adults with cardiometabolic disease or who are at future risk of cardiometabolic disease.